Kornimate/medical-research-clean huggingface dataset:
pilot study of efficacy of nail gel in finger nail surface abnormality

Conditions: Nail Abnormalities

Summary: nail surface abnormalities is any conditions that affect the nail matrix or nail bed which cause nail plates grow defectively. common nail surface abnormalities are pitting nails, longitudinal ridging, and transverse ridging/beau's line. aging nails usually have nail surface abnormalities as well. nail gels are artificial nails used widely for aesthetic purposes. although, their cosmetic use is increasing with day by day, their usefulness in conditions such as nail biting, brittle nails, and ingrown toe nails has been reported. moreover, a previous study reported the benefits of nail gels in terms of improving nail surface abnormalities like pitting nails, trachyonychia, and onychoschizia. this study was conducted to evaluate the efficacy of nail gel containing glycerin which has humectant effect and artemisia abrotanum extract which has anti-fungal/bacterial activities in finger nail surface abnormalities.

evaluation of nail surface abnormality can be done by using visiometer® (bioengineering measurement) and dermoscope. both techniques are non-invasive. artemisia abrotanum extract has been used as ingredient in cosmetic products and its safety has been declared. undesirable events from external using products containing this substance have never been reported yet. nail gel product in this study has been approved as a cosmetic product by food and drug administration of thailand (thai fda).

Eligibility criteria:
inclusion criteria: 1. age 18 years old or above 2. being diagnosed nail surface abnormalities stably more than 3 months exclusion criteria: 1. having severe or uncontrolled concomitant diseases 2. having nail infection 3. history of manicure within the last 1 month 4. use of biotin or other nail modifying drugs within the previous 3 months 5. pregnancy or lactation

Keywords: nail gel nail surface abnormality efficacy
restoration of beta cell function and cardiovascular parameters in relation to adipoinsular and enteroinsular axes after gastric bypass surgery

Conditions: Diabetes Mellitus, Type 2; Bariatric Surgery Candidate

Summary: bariatric operations such as the gastric bypass procedure provide a unique in vivo model of improvement of pathological beta cell function. the presented double-centre study aims to comprehensively investigate different aspects of beta cell function in patients with type 2 diabetes (t2dm) with a wide range of disease duration after gastric bypass. in parallel, our project will address the aspects of changes in enteroinsular and adipoinsular axes as well as the early and late changes of other defined parameters after gastric bypass surgery.


Eligibility criteria:
inclusion criteria: * \> 18 years * indication forbariatric surgery or non-bariatric abdominal surgery exclusion criteria: * pregnancy

Keywords: resolvment of diabetes mellitus, type 2 gastric bypass
exercise prescription dose for castration resistance prostate cancer patients

Conditions: Prostatic Neoplasms; Exercise; Castration-resistant Prostate Cancer; Physical Activity

Summary: recent drug improvement (e.g. abiraterone or enzalutamide) for castration resistant prostate cancer (crpc) patients has improved survival. as treatment strategies improve and patients live longer, patients must cope with their treatment-induced adverse effects. improving levels of physical activity (pa) and less amounts of sitting time (e.g. sedentary behavior, sb) could have a positive impact on patient's health, non-cancer mortality, and quality of life and potentially improve survival. the role of pa has not yet been examined in crpc patients, which is a clear unmet need. no specific pa guidelines exist for crpc patients, but specific guidelines are warranted because of advanced disease stage, reduced performance score and comorbidity. it is to be expected that the pa level of crpc patients is lower compared to non-crpc patients receiving androgen deprivation therapy (adt). this study aims to determine the optimal starting physical therapy prescription in crpc patients receiving second line hormone treatment.

crpc patients receiving second-line hormone treatment at ghent university hospital are invited to participate in this phase i 3+3 dose escalation design (escalation to next exercise dose per 3 study patients). the prescription start dose is 15min. aerobic training (50-80% maximum heart rate (hrmax). warm-up and cooling-down and 65-80%hrmax. core), 1 set with 8-10 reps. resistance training (50-60% one repetition maximum (1rm), 8 exercises) and 1 set (30s.) with 2 reps. flexibility training (5 exercises). factors determining compliance for the dose are tolerance and safety. tolerance for the exercise prescription will be assessed with the borg scale of perceived exertion after every exercise. compliant for tolerance is a score ≤16. safety will be assessed by the visual analogue scale (vas) (assessed by the patient) for pain and the ctcae criteria (assessed by a trained health care provider) for bone pain after every exercise. compliant for safety is ≤3 vas for exercise-induced pain and \<grade 2 according to the ctcae criteria.

Eligibility criteria:
inclusion criteria: * crpc patients with second-line hormone treatment * able to walk 400 meters without help from another person * absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule (those conditions should be discussed with the patient before registration in the trial) * ≥4 weeks since any major surgery and fully recovered before patient registration * written informed consent must be given according to international conference on harmonization good clinical practice and national regulation. exclusion criteria: * musculoskeletal, cardiovascular or neurological comorbidity that prevent the patient to participate in an exercise program * painful bone metastases (vas) at the time of inclusion * unstable bone metastases (sins classification) at time of inclusion
establishment and application of an artificial intelligence algorithm for automatic identification of intraoperative bleeding during laparoscopic pancreaticoduodenectomy

Conditions: Laparoscopic Pancreaticoduodenectomy

Summary: surgeons will label surgical videos of laparoscopic pancreaticoduodenectomy with bleeding information from multicenter. the labeled surgical video will be used as training material to train the algorithmic model so as to build an artificial intelligence algorithm that can automatically identify intraoperative bleeding in this surgery. then, we will test the performance capability of the algorithm.


Eligibility criteria:
inclusion criteria: 1. surgical videos that recorded complete laparoscopic pancreaticoduodenectomy including resection and reconstruction phases. exclusion criteria: 1.surgical videos that recorded laparoscopic pancreaticoduodenectomy combined with resection and reconstruction of mesentericoportal vein.

Keywords: laparoscopic pancreaticoduodenectomy surgical videos artificial intelligence
transit time flow measurement in coronary surgery

Conditions: Coronary Artery Disease; Coronary Stenosis; Coronary Bypass Graft Stenosis

Summary: transit-time flowmetry (ttfm) allows grafts quality control during coronary artery bypass surgery by measuring the flow volume through them. to date, many studies have deeply studied the predictive role on the graft outcomes of the various flowmetry-derived parameters. one of the least investigated aspects, however, is the mutual influence that two newly realized grafts can have. this possibility would be related to the presence of a more or less developed collateral circulation between the bypassed territories. the purpose of this study is to assess whether a graft for a territory different than that provided by the left anterior descending artery (lad) may affect the functionality (measured through flowmetry) of the left internal mammary artery - lad graft.


Eligibility criteria:
inclusion criteria: * age \> 18 years; * informed consent acquired and registered; * patients who undergo coronary artery bypass grafting (with or without cardiopulmonary bypass); * patients with stable angina, unstable angina or acute coronary syndrome without elevation of the st tract (nstemi) exclusion criteria: * patients unable to give informed consent; * patients undergoing emergency surgery; * patients in unstable haemodynamic conditions or in need of pharmacological or mechanical support; * patients undergoing combined surgery; * patients undergoing single aortocoronary bypass surgery

Keywords: coronary artery bypass transit time flowmetry intraoperative epicardial high-frequency ultrasound (hfus) coronary anastomosis patency
gastroparesis in type2 diabetic patient

Conditions: Diabetic Gastroparesis

Summary: gastroparesis is defined by objective delaying of gastric emptying without any evidence of mechanical obstruction. diabetic gastroparesis is a potential complication that occurs in the setting of poorly controlled diabetes, resulting from dysfunction in the coordination and function of the autonomic nervous system, neurons, and specialized pacemaker cells (interstitial cells of cajal, icc) of the stomach and intestine, and the smooth muscle cells of the gastrointestinal tract

hyperglycemia (random blood glucose greater than 200 mg/dl), commonly seen in uncontrolled diabetes, has been associated with diabetic gastroparesis resulting from neuropathy in the setting of chronic hyperglycemia and does not resolve with improved glycemic control. acute hyperglycemia, on the other hand, though it can also result in delayed gastric emptying, is often reversible with improved glycemic control. although there is a stronger association between type 1 diabetes and gastroparesis, the incidence of type 2 diabetes is much greater, and therefore, gastroparesis associated with type 2 diabetes is seen more frequently. additionally, incretin mimetics are used to treat patients with type 2 diabetes, and these medications pose an additional risk factor for developing gastroparesis.gastric emptying scintigraphy (ges) is the investigation of choice for evaluating the disorders of gastric emptying because it is a simple, physiological, and sensitive investigation to objectively assess gastric emptying. standard imaging is performed at 0,1,2,4 hours postprandially. a four-hour study is more sensitive and accurate in diagnosing gastroparesis, and clinicians should avoid shortened 2- and 3-hour studies.

Eligibility criteria:
inclusion criteria: 1. type 2 dm 2. age \< 40 years 3. \>5 years of dm exclusion criteria: 1. type 1 dm 2. history of git surgry 3. medical disease affect gastric emptying 4. using of prokinetic
tetris to reduce intrusive memories in parents after picu

Conditions: Post-traumatic Stress Disorders

Summary: the purpose of this study is to examine the acceptability and feasibility of a brief behavioural intervention involving tetris gameplay to prevent intrusive traumatic memories in parents after paediatric intensive care. the present acceptability and feasibility study seeks to answer the following questions: (1) is this intervention acceptable to parents whose children have been admitted to picu, (2) how practical is it to deliver the intervention in this setting, (3) willingness of hospital staff to be involved in the recruitment of participants, (4) after having taken part in the intervention themselves would parents have been willing to consent to their child taking part in the intervention, and (5) discover any challenges or barriers in carrying out this study. furthermore, this study aims to estimate recruitment, withdrawal and dropout rate, in order to act as a preliminary test of the effect of the intervention and inform sample size estimation. the findings from this study will inform the design of a randomised control trial.


Eligibility criteria:
inclusion criteria: * parent of a child in picu, therefore exposed to an event meeting dsm-5 criterion for a traumatic event (apa, 2013). * the parent's child must be near the point of discharge from picu (site 1 and 2), as identified by a clinician, or on a paediatric hospital ward within 24 hours after discharge from picu (site 2 only). * sufficient ability to read and understand english to provide consent, follow game instructions and complete measures. * have sufficient physical mobility to play tetris using a computer (e.g. a handheld nintendo ds). * willing and able to complete measures and be contacted one-week and month post-intervention to complete follow-up measures. exclusion criteria: * parents will be excluded from the study if their child is due to be discharged to palliative care and/or if nursing/medical staff within the picu feel it would be inappropriate to contact them/have them participate in this study.
assessment of nerve damage biomarkers in acute and chronic organophosphate toxicity

Conditions: Neuroinflammatory Response; Nerve Injury; Nerve Damage; Neurotoxicity; Nerve Degeneration; Genotoxicity

Summary: the aim of this observational study is to answer the following questions in individuals with acute and chronic exposure to organophosphates. the main questions to be addressed are 1. what are the prognostic values of neuroinflammatory markers? 2. what are the genotoxic effects of organophosphates? 3. what are the changes occurring in the levels of traditional oxidative stress and inflammatory markers?

this is a cross-sectional study that aims to assess the possible prognostic value of markers of neuroinflammation and nerve damage in patients with acute and chronic exposure to organophosphate pesticides by conducting a full proteomic and metabolomic profile. the possible genotoxic effect of common organophosphate pesticides will be studied as well. this will be conducted in parallel to the assessment of traditional markers of inflammation and oxidative stress. the target populations are patients with acute and chronic exposure to organophosphates with a total estimated number of 90 including individuals assigned to the control group with matched age and gender.

Eligibility criteria:
inclusion criteria: * for the control group: healthy individuals without previous exposure to organophosphates, with the specified age limits. * for the acute exposure group: patients with acute exposure to organophosphates, with the specified age limits * for the chronic exposure group: patients with chronic exposure to organophosphates, with the specified age limits no restrictions on comorbidities in the three groups except those mentioned under exclusion criteria exclusion criteria: * pediatric patients. * patients with neurological diseases (parkinsonism, epilepsy, alzheimer's disease, etc.) * patients who does not meet the inclusion criteria.

Keywords: organophosphates neuroinflammatory biomarkers metabolomic and proteomic analysis oxidative stress biomarkers nerve damage acute and chronic toxicity neuroinflammation inflammatory response pesticides acetyl choline esterase enzyme inhibition
pharmacodynamics, safety and efficacy of topical omiganan in patients with external genital warts

Conditions: Condylomata Acuminata (External)

Summary: the purpose of this study is to assess the pharmacodynamics, safety and efficacy of omiganan in patients with external genital warts.


Eligibility criteria:
inclusion criteria: 1. healthy male and female subjects ≥ 18 years of age, with external genital warts. the health status is verified by absence of evidence of any clinical significant active or uncontrolled chronic disease other than genital warts following a detailed medical history and a complete physical examination including vital signs and 12-lead ecg. in the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility or judged to be clinically irrelevant for healthy subjects. 2. clinically diagnosed and biopsy confirmed external genital warts. subject has at least 3 external genital warts. 3. willing to give written informed consent and willing and able to comply with the study protocol. exclusion criteria: eligible subjects must meet none of the following exclusion criteria at screening: 1. clinically significant abnormalities, as judged by the investigator, in laboratory test results including haematology, blood chemistry panel, virology or urinalysis. in the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility or judged to be clinically irrelevant for healthy subjects. 2. current clinically significant skin conditions in the anogenital area (e.g. atopic dermatitis, lichen sclerosus, lichen planus or psoriasis). 3. pregnant, breast feeding or trying to conceive. 4. participation in an investigational drug or device study within 3 months prior to screening or more than 4 times a year. 5. loss or donation of blood over 500 ml within three months (males) or four months (females) prior to screening. 6. use of active treatment (i.e. cryotherapy, laser therapy, topical medication and/or surgical treatments) for genital warts within 28 days prior to first study drug administration. 7. immunosuppressed patients, having an immunodeficiency (primary or secondary, like hiv) or receiving immunosuppressive therapy (i.e. transplant patients). 8. males or females who received a vaccination with gardasil or cervarix. 9. any (medical) condition that would, in the opinion of the investigator, potentially compromise the safety or compliance of the patient or may preclude the patient's successful completion of the clinical trial.
tumor antigen discovery for innovative cancer immunotherapies in hcc: from benchside to bedside (hepant)

Conditions: Hepatocellular Carcinoma

Summary: tumor antigen discovery for innovative cancer immunotherapies in hcc: from benchside to bedside (hepant) - study of the role of the metagenome in head and neck tumors using omics techniques (henomics).

the aim of this study is to: * analyze and compare the microbiota and the intestinal, salivary and intratumoral microbiome in patients with hcc, patients diagnosed with oncological pathology and in healthy subjects. the analysis of the mycobiota will be carried out by analyzing bacterial culture media, that of the microbiome by genomic analysis. the evaluation will be made by taking into account multiple taxonomic levels: phylum, class, order, family, genus and species. * identify tumor antigens (tuas) with sequence homology with peptides derived from the microbiota/microbiome by bioinformatic analysis. the sequences of tumor antigens known from the literature (https://caped.icp.ucl.ac.be/peptide/list) will be aligned with sequences derived from bacteria identified in the microbiota/microbiome of patients and healthy subjects.

Eligibility criteria:
inclusion criteria: * histological diagnosis of primary hcc and other oncological pathology (pascale institute) or diagnosis of oncological pathology (without any exclusions) from an accredited medical-clinical facility (fortore mountain community). * age ≥18 years * ability to give signed informed consent that includes compliance with the requirements and constraints listed in the informed consent form (icf) and in this protocol. * in the case of paraffin-embedded samples obtained from the uoc of pathological anatomy and/or the institute's biological bank, informed consent cannot be acquired, in accordance with the provision of the privacy authority containing the requirements relating to the processing of special categories of data, pursuant to art. 21, paragraph 1 of legislative decree 10 august 2018, no. 101, published in the official journal - general series - no. 176 of 29/07/2019, point 5 "provisions relating to the processing of personal data carried out for scientific research purposes (gen. aut. n. 9/2016)" healthy subjects * clinical history free from diagnosis of tumor or neoplastic pathology treated during life * age ≥80 years * ability to give signed informed consent that includes compliance with the requirements and constraints listed in the informed consent form (icf) and in this protocol exclusion criteria: * current pathologies requiring antibiotic therapy * diagnosis of pre-tumor pathology (in healthy subjects)
liraglutide in overweight patients with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: the purpose of this study is to examine the effects of liraglutide (a drug used to treat type 2 diabetes) on glucose (sugar) control over the 26 week study period when used in addition to insulin.


Eligibility criteria:
inclusion criteria: 1) type 1 diabetes on continuous subcutaneous insulin infusion (csii; also known as insulin pump) or multiple (four or more) injections of insulin per day. 2) using a continuous glucose monitoring device (cgm) or regularly measuring their blood sugars four times daily. 3) hba1c of less than 8.5%. 4) well versed with carbohydrate counting. 5) age 18-75 years 6) bmi≥ 25kg/m2 7) age at diagnosis of type 1 diabetes should be \<30 years. 8) evidence of auto-immunity to beta cells (gad-65 and islet cell antibody screen) exclusion criteria: 1)type 1 diabetes for less than 6 months; 2)coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks; 3)hepatic disease (transaminase \> 3 times normal) or cirrhosis; 4)renal impairment (serum egfr \<30ml/min/1.73m2); 5)hiv or hepatitis b or c positive status; 6)participation in any other concurrent clinical trial; 7)any other life-threatening, non-cardiac disease; 8)use of an investigational agent or therapeutic regimen within 30 days of study. 9) history of pancreatitis 10) pregnancy 11) inability to give informed consent 12) history of gastroparesis 13)history of medullary thyroid carcinoma or men 2 syndrome. 14) smokers will be advised not to change their amount of smoking for the duration of the study; 15) use of any agent other than insulin for treatment of diabetes (metformin, pramlintide or thiazolidinediones.